MEDP vs PRA

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -2. 7% for ProAssurance Corporation (PRA). ProAssurance Corporation (PRA) offers the better valuation at 24. 8x trailing P/E (21. 8x forward), making it the more compelling value choice. Analysts rate Medpace Holdings, Inc. (MEDP) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ProAssurance Corporation (PRA) is the cheapest at 24.

8x versus Medpace Holdings, Inc. at 27. 9x. On forward P/E, ProAssurance Corporation is actually cheaper at 21. 8x.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -4. 4% for ProAssurance Corporation (PRA). Over 10 years, the gap is even starker: MEDP returned +1436% versus PRA's -18. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ProAssurance Corporation (PRA) is the lower-risk stock at 0.

05β versus Medpace Holdings, Inc. 's 1. 26β — meaning MEDP is approximately 2515% more volatile than PRA relative to the S&P 500. On balance sheet safety, ProAssurance Corporation (PRA) carries a lower debt/equity ratio of 32% versus 55% for Medpace Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -2. 7% for ProAssurance Corporation (PRA). On earnings-per-share growth, the picture is similar: Medpace Holdings, Inc. grew EPS 21. 0% year-over-year, compared to -3. 9% for ProAssurance Corporation. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus 4. 6% for ProAssurance Corporation — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 6. 6% for PRA. At the gross margin level — before operating expenses — PRA leads at 39. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ProAssurance Corporation (PRA) trades at 21.

8x forward P/E versus 25. 1x for Medpace Holdings, Inc. — 3. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MEDP: 16. 9% to $498. 86.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ProAssurance Corporation (PRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05)). Both have compounded well over 10 years (PRA: -18. 0%, MEDP: +1436%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MEDP (Healthcare) and PRA (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MEDP is a mid-cap high-growth stock; PRA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.